Skip to main content
Evidence Snapshot

Complement C1s subcomponent

CHEMBL3913 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:50:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3913
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Complement C1s subcomponent as ChEMBL target CHEMBL3913, mapped to UniProt P09871. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Complement C1s subcomponent
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3913
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P09871
Complement C1s subcomponent
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Complement C1s subcomponent matters

As of 2026-09-13

Complement C1s subcomponent is reviewed as Complement C1s subcomponent (UniProt P09871); Complement C1s subcomponent shows approved-linked disease relevance led by Anemia, Hemolytic, Autoimmune. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 200 compounds, and 29 assays, with lead potency reaching pChEMBL 8.8.

Disease context
Anemia, Hemolytic, Autoimmune

Complement C1s subcomponent shows approved-linked disease relevance led by Anemia, Hemolytic, Autoimmune. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include SUTIMLIMAB.

Start review with Anemia, Hemolytic, Autoimmune because it currently carries approved-linked support. Linked drugs include SUTIMLIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 0 approved drugs, 200 compounds, and 29 assays for this target. The dominant activity type is KI. CHEMBL2220483 is the current potency anchor at pChEMBL 8.8.

Use CHEMBL2220483 as the tractability anchor when discussing potency (pChEMBL 8.8).

Activity source · ChEMBL 36 via Core Engine
pChEMBL 8.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Complement C1s subcomponent matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P09871, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Anemia, Hemolytic, Autoimmune is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

200
Total Compounds
29
Total Assays
0
Approved Drugs
IC50: 50.0, KI: 154.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2220483
 8.8 IC50 —
No preferred name
CHEMBL5723340
 8.8 IC50 —
No preferred name
CHEMBL4244141
 8.2 Ki —
No preferred name
CHEMBL5435382
 8.2 IC50 —
No preferred name
CHEMBL205904
 8.0 Ki —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:50:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3913